[go: up one dir, main page]

WO2018193090A3 - Process for preparation of eliglustat hemitartrate and intermediates thereof - Google Patents

Process for preparation of eliglustat hemitartrate and intermediates thereof Download PDF

Info

Publication number
WO2018193090A3
WO2018193090A3 PCT/EP2018/060185 EP2018060185W WO2018193090A3 WO 2018193090 A3 WO2018193090 A3 WO 2018193090A3 EP 2018060185 W EP2018060185 W EP 2018060185W WO 2018193090 A3 WO2018193090 A3 WO 2018193090A3
Authority
WO
WIPO (PCT)
Prior art keywords
intermediates
preparation
eliglustat hemitartrate
eliglustat
hemitartrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2018/060185
Other languages
French (fr)
Other versions
WO2018193090A2 (en
Inventor
Kanaram Hanumanprasad KUMAWAT
Brijesh Rajendrakumar PATEL
Nilesh Mansukhlal Thumar
Joseph Prabahar UPADHYAY
Joseph Prabahar Koilpillai
Virendrakumar Agarwal
Parva Yogeshchandra Purohit
Arif Badrulhusan Siddiqui
Krushnakant Natvarbhai PATEL
Vipul Veljibhai GONDALIYA
Ankit Ramjibhai BUHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amneal Pharmaceuticals Co GmbH
Original Assignee
Amneal Pharmaceuticals Co GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amneal Pharmaceuticals Co GmbH filed Critical Amneal Pharmaceuticals Co GmbH
Publication of WO2018193090A2 publication Critical patent/WO2018193090A2/en
Publication of WO2018193090A3 publication Critical patent/WO2018193090A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci. Elle concerne également des compositions pharmaceutiques stables à forme amorphe d'hémitartrate d'eliglustat comprenant la forme amorphe d'hémitartrate d'eliglustat, ainsi que leurs utilisations.The invention relates to a process for the preparation of eliglustat hemitartrate and intermediates thereof. It also relates to stable amorphous form of eliglustat hemitartrate pharmaceutical compositions comprising the amorphous form of eliglustat hemitartrate, as well as their uses.

PCT/EP2018/060185 2017-04-21 2018-04-20 Process for preparation of eliglustat hemitartrate and intermediates thereof Ceased WO2018193090A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721014151 2017-04-21
IN201721014151 2018-03-05

Publications (2)

Publication Number Publication Date
WO2018193090A2 WO2018193090A2 (en) 2018-10-25
WO2018193090A3 true WO2018193090A3 (en) 2019-01-03

Family

ID=62111029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/060185 Ceased WO2018193090A2 (en) 2017-04-21 2018-04-20 Process for preparation of eliglustat hemitartrate and intermediates thereof

Country Status (1)

Country Link
WO (1) WO2018193090A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120115972A (en) 2009-11-27 2012-10-19 젠자임 코포레이션 An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
CN110759885B (en) * 2018-07-27 2021-10-22 中国医学科学院药物研究所 Method for preparing photoactive igloot
CN110878079A (en) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 Preparation method of high-purity eliagliptat
WO2020194138A1 (en) 2019-03-22 2020-10-01 Piramal Enterprises Limited An improved process for the preparation of eliglustat and its intermediate
CN116120274A (en) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 Pharmaceutically acceptable salts of irinotecan and crystalline forms thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101558A1 (en) * 2003-05-13 2004-11-25 F. Hoffmann-La Roche Ag 2-imidazo-benzothiazoles as adenosine receptor ligands
US7615753B2 (en) * 2003-12-30 2009-11-10 Commissariat A L'energie Atomique Radiation detecting system with double resetting pulse count
WO2011066352A1 (en) * 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE555102T1 (en) 2001-07-16 2012-05-15 Genzyme Corp N-ACYLSPHINGOSINE LUCOSYLTRANSFERASE INHIBITOR
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20170129869A1 (en) 2014-07-03 2017-05-11 Dr. Reddy's Laboratories Limited Amorphous form of eliglustat hemitartarate
CN105646442A (en) 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 Preparation method of eliglustat

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101558A1 (en) * 2003-05-13 2004-11-25 F. Hoffmann-La Roche Ag 2-imidazo-benzothiazoles as adenosine receptor ligands
US7615753B2 (en) * 2003-12-30 2009-11-10 Commissariat A L'energie Atomique Radiation detecting system with double resetting pulse count
WO2011066352A1 (en) * 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"/1 -(C) FILE REGISTRY RN -2138286-91-4 REGISTRY ED -Entered STN: 02 Nov 2017 CN -Octanamide, N-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxo-1-(1- pyrrolidinylmethyl)ethyl]-(CA INDEX NAME) MF -C23 H34 N2 O4 SR -Chemical Catalog Supplier: Enamine LLC LC -STN Files: CHEMCATS", 2 November 2017, article CHEMICAL ABSTRACTS OHIO: "/1 -(C) FILE REGISTRY RN -2138286-91-4 REGISTRY ED -Entered STN: 02 Nov 2017 CN -Octanamide, N-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxo-1-(1- pyrrolidinylmethyl)ethyl]-(CA INDEX NAME) MF -C23 H34 N2 O4 SR -Chemical Catalog Supplier: Enamine LLC LC -STN Files: CHEMCATS", XP055491732 *

Also Published As

Publication number Publication date
WO2018193090A2 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
WO2018193090A3 (en) Process for preparation of eliglustat hemitartrate and intermediates thereof
MA45809A (en) PRE-MEDICINES FOR PTH
MX2020006957A (en) Modified release composition comprising a cannabinoid.
WO2019133770A3 (en) Glycolate oxidase inhibitors for the treatment of disease
WO2013091775A3 (en) Use of cyclohexanol derivatives as antimicrobial active ingredients
BR112014007163A2 (en) n-methyl-2 [3 ((e) -2-pyridin-2-yl-vinyl) -1h-indazol-6-ylsulfanyl] -benzamide pharmaceutical compositions
EP4252848A3 (en) Oxysterols and methods of use thereof
EP4609866A3 (en) Oxysterols and methods of use thereof
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
WO2018224063A3 (en) Solid forms of elagolix
MX383804B (en) PIPERIDINE DERIVATIVES.
MA46490A1 (en) Substituted 4'- fluoro-2 '- methyl nucleoside derivatives
EP4327880A3 (en) Solid state form of ribociclib succinate
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
MA49560B1 (en) BICYCLIC KETONE COMPOUNDS AND METHODS OF USE
MA33679B1 (en) 2-OXO-1-PYRROLIDINYL DERIVATIVES IMIDAZOTHIADIAZOLE
EP3694330A4 (en) INDAZOLYL-SPIRO [2.2] PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THEIR USES
MA38678A1 (en) Nucleoside derivatives 4'-azido, 3'-deoxy-3'-fluoro substituted
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
MA38679A1 (en) Cxcr7 receiver modulators
CA3031343C (en) Salts of 2,6-dimethylpyrimidone derivatives and uses thereof
MA41174B1 (en) Imidazopyridazine derivatives used as pi3kbeta inhibitors
EP3760195A4 (en) COMPOSITION COMPRISING 2,3-BUTANEDIOL AS ACTIVE INGREDIENT
MA39229A1 (en) Pyrrolidines, terrahydrofurans and substituted cyclopentanes useful as orexin receptor antagonists
WO2011014003A3 (en) (+)-3-hydroxymorphinan derivatives as neuroprotectants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18721974

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18721974

Country of ref document: EP

Kind code of ref document: A2